Skip to content
10-Q

Quarterly Report

Arbutus Biopharma Corp ABUS

0001447028-26-000021

← back to feed
Filed
May 13, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 11, 2026 197.54M sh
Shares Diluted Q1 2026 · Mar 31, 2026 195.21M sh
Shares Diluted Q1 2026 · Mar 31, 2025 190.71M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$8.11M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$13.39M
Long Term Debt Q1 2026 · Mar 31, 2026 $0
Cash And Equivalents Q1 2026 · Mar 31, 2026 $23.71M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $18.01M
Stockholders Equity Q1 2026 · Mar 31, 2026 $260.18M
Stockholders Equity Q1 2026 · Dec 31, 2025 $76.58M
Stockholders Equity Q1 2026 · Mar 31, 2025 $79.16M
Stockholders Equity Q1 2026 · Dec 31, 2024 $97.37M
Current Liabilities Q1 2026 · Mar 31, 2026 $5.11M
Current Liabilities Q1 2026 · Dec 31, 2025 $6.01M
Total Liabilities Q1 2026 · Mar 31, 2026 $16.99M
Total Liabilities Q1 2026 · Dec 31, 2025 $18.04M
Current Assets Q1 2026 · Mar 31, 2026 $277.01M
Current Assets Q1 2026 · Dec 31, 2025 $94.46M
Total Assets Q1 2026 · Mar 31, 2026 $277.16M
Total Assets Q1 2026 · Dec 31, 2025 $94.62M
Eps Diluted Q1 2026 · Mar 31, 2026 $0.87
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.13
Eps Basic Q1 2026 · Mar 31, 2026 $0.88
Eps Basic Q1 2026 · Mar 31, 2025 −$0.13
Sga Expense Q1 2026 · Mar 31, 2026 $5.89M
Sga Expense Q1 2026 · Mar 31, 2025 $5.83M
Rd Expense Q1 2026 · Mar 31, 2026 $4.12M
Rd Expense Q1 2026 · Mar 31, 2025 $8.96M
Net Income Q1 2026 · Mar 31, 2026 $169.7M
Net Income Q1 2026 · Mar 31, 2025 −$24.53M
Operating Income Q1 2026 · Mar 31, 2026 $168.91M
Operating Income Q1 2026 · Mar 31, 2025 −$25.7M
Revenue Q1 2026 · Mar 31, 2026 $179.13M
Revenue Q1 2026 · Mar 31, 2025 $1.76M